Brain uptake of a non-radioactive pseudo-carrier and its effect on the biodistribution of [18 F]AV-133 in mouse brain.
- Resource Type
- Article
- Authors
- Wu, Xianying; Zhou, Xue; Zhang, Shuxian; Zhang, Yan; Deng, Aifang; Han, Jie; Zhu, Lin; Kung, Hank F.; Qiao, Jinping
- Source
- Nuclear Medicine & Biology. Jul2015, Vol. 42 Issue 7, p630-636. 7p.
- Subject
- *RADIOACTIVE substances
*BRAIN physiology
*LABORATORY mice
*POSITRON emission tomography
*SOLID phase extraction
*MONOAMINE transporters
- Language
- ISSN
- 0969-8051
Introduction 9-[ 18 F]Fluoropropyl-(+)-dihydrotetrabenazine ([ 18 F]AV-133) is a new PET imaging agent targeting vesicular monoamine transporter type II (VMAT2). To shorten the preparation of [ 18 F]AV-133 and to make it more widely available, a simple and rapid purification method using solid-phase extraction (SPE) instead of high-pressure liquid chromatography (HPLC) was developed. The SPE method produced doses containing the non-radioactive pseudo-carrier 9-hydroxypropyl-(+)-dihydrotetrabenazine (AV-149). The objectives of this study were to evaluate the brain uptake of AV-149 by UPLC-MS/MS and its effect on the biodistribution of [ 18 F]AV-133 in the brains of mice. Methods The mice were injected with a bolus including [ 18 F]AV-133 and different doses of AV-149. Brain tissue and blood samples were harvested. The effect of different amounts of AV-149 on [ 18 F]AV-133 was evaluated by quantifying the brain distribution of radiolabelled tracer [ 18 F]AV-133. The concentrations of AV-149 in the brain and plasma were analyzed using a UPLC-MS/MS method. Results The concentrations of AV-149 in the brain and plasma exhibited a good linear relationship with the doses. The receptor occupancy curve was fit, and the calculated ED 50 value was 8.165 mg/kg. The brain biodistribution and regional selectivity of [ 18 F]AV-133 had no obvious differences at AV-149 doses lower than 0.1 mg/kg. With increasing doses of AV-149, the brain biodistribution of [ 18 F]AV-133 changed significantly. Conclusion The results are important to further support that the improved radiolabelling procedure of [ 18 F]AV-133 using an SPE method may be suitable for routine clinical application. [ABSTRACT FROM AUTHOR]